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Abstract
Background: Duchenne muscle dystrophy (DMD) afflicts 1 million boys in the US and has few effective treatments.
Constitutive transgenic expression of the transcriptional coactivator peroxisome proliferator-activated receptor
gamma coactivator (PGC)-1α improves skeletal muscle function in the murine “mdx” model of DMD, but how this
occurs, or whether it can occur post-natally, is not known. The leading mechanistic hypotheses for the benefits
conferred by PGC-1α include the induction of utrophin, a dystrophin homolog, and/or induction and stabilization
of the neuromuscular junction.
Methods: The effects of transgenic overexpression of PGC-1β, a homolog of PGC-1α in mdx mice was examined
using different assays of skeletal muscle structure and function. To formally test the hypothesis that PGC-1α confers
benefit in mdx mice by induction of utrophin and stabilization of neuromuscular junction, PGC-1α transgenic
animals were crossed with the dystrophin utrophin double knock out (mdx/utrn
-/-) mice, a more severe dystrophic
model. Finally, we also examined the effect of post-natal induction of skeletal muscle-specific PGC-1α
overexpression on muscle structure and function in mdx mice.
Results: We show here that PGC-1β does not induce utrophin or other neuromuscular genes when transgenically
expressed in mouse skeletal muscle. Surprisingly, however, PGC-1β transgenesis protects as efficaciously as PGC-1α
against muscle degeneration in dystrophin-deficient (mdx) mice, suggesting that alternate mechanisms of
protection exist. When PGC-1α is overexpressed in mdx/utrn
-/- mice, we find that PGC-1α dramatically ameliorates
muscle damage even in the absence of utrophin. Finally, we also used inducible skeletal muscle-specific PGC-1α
overexpression to show that PGC-1α can protect against dystrophy even if activated post-natally, a more plausible
therapeutic option.
Conclusions: These data demonstrate that PGC-1α can improve muscle dystrophy post-natally, highlighting its
therapeutic potential. The data also show that PGC-1α is equally protective in the more severely affected mdx/utrn
-/-
mice, which more closely recapitulates the aggressive progression of muscle damage seen in DMD patients. The
data also identify PGC-1β as a novel potential target, equally efficacious in protecting against muscle dystrophy.
Finally, the data also show that PGC-1α and PGC-1β protect against dystrophy independently of utrophin or of
induction of the neuromuscular junction, indicating the existence of other mechanisms.
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Duchenne muscle dystrophy (DMD) is an inexorably
fatal recessive X-linked hereditary disease that affects 1
in 3,600 boys in the US and is marked by progressive
muscle dystrophy that ultimately leads to paralysis and
respiratory and/or cardiac failure [1-5]. The disease is
caused by mutations in the dystrophin gene, which en-
codes for a critical component of the dystroglycan com-
plex (DGC) that connects the extracellular matrix of
muscle fibers to the cytoskeleton [4,6,7]. Dysfunctional
DGC leads to excess intracellular calcium, mitochondrial
dysfunction, loss of sarcolemmal integrity, and ultimately
cell death, but the precise pathogenesis of DMD remains
unclear [4,6,8]. Therapeutic options for DMD remain lim-
ited, and no significant pharmacological advances have
been made since the introduction of steroids in the 1970s
[1-3]. A deeper understanding of protective mechanisms
is needed.
Utrophin is an important component of the neuromus-
cular junction (NMJ) and bears significant sequence and
functional homology to dystrophin [9,10]. Dystrophin-
deficient (mdx) mice, in which the dystrophin gene is
mutated, are widely used as a model of DMD, and genetic
deletion of utrophin superimposed on the mdx back-
ground greatly worsens the observed dystrophy, con-
sistent with redundant function between utrophin and
dystrophin [10-15]. The dystrophin utrophin double
knock-out mouse (mdx/utrn
-/-)m o d e l st h es e v e r i t yo f
human DMD phenotype more faithfully than the par-
ental dystrophin knock-out (mdx) mouse [11,12,15].
Conversely, transgenic expression of utrophin in skel-
etal muscle significantly improves indices of dystrophy
in mdx mice [3,10,16]. Utrophin has thus been proposed
as a potential therapeutic target, and efforts are underway
to translate these observations to the clinical setting.
Transgenic overexpression in skeletal muscle of per-
oxisome proliferator-activated receptor gamma coactiva-
tor (PGC)-1α has also been shown to markedly improve
dystrophy in mdx mice [17]. PGC-1α powerfully regulates
broad programs of gene expression by binding to, and co-
activating, numerous transcription factors [18-20]. In most
tissues, including skeletal muscle, PGC-1α strongly in-
duces mitochondrial biogenesis by co-activating nuclear
respiratory factor 1 (NRF1), NRF2, estrogen-related recep-
tor α (ERRα), and other transcription factors. At the same
time, PGC-1α induces the expression of a number of ancil-
lary programs, including fatty acid transport and oxidation
[21-23]. PGC-1β, a homolog that bears extensive sequence
identity with PGC-1α in a number of functional domains,
shares many, though not all, of these functions [24-28].
In skeletal muscle, PGC-1α also induces genes that en-
code components of the neuromuscular junction [17,29].
NRF2, composed of a hetero-tetramer of GA-binding
protein α chain (GABPA) and GA-binding protein β
chain (GABPB), was in fact independently identified as a
key transcription factor in the regulation of NMJ genes.
Consistent with this, PGC-1α strongly induces utrophin
expression both in cells and in mice that transgenically
overexpress PGC-1α in skeletal muscle [17,29,30]. As
noted above, these same transgenic mice markedly im-
prove dystrophy in the mdx background [17]. This
strong protection has thus widely been ascribed to the
induction of utrophin by PGC-1α [17,31-34], although
this has never formally been tested. It is also not clear
when in development the induction of PGC-1α is most
critical, because prenatal changes in dystrophin-deficient
muscle means that prenatal expression of PGC-1α may
have had important effects [35,36].
H e r e ,w eu s ev a r i o u st r a n s g e n i cm i c et ot e s ti fi n d u c -
tion of utrophin by PGC-1α is necessary for amelior-
ation of muscle damage in DMD models. We find that
PGC-1α surprisingly protects against dystrophy inde-
pendently of utrophin. In fact, PGC-1α efficiently protects
the mdx/utrn
-/- mice, which, as noted above, model the
severity of human DMD more faithfully than the parental
mdx mouse [15]. We also show that PGC-1β protects
against dystrophy as efficaciously as PGC-1α, even though
PGC-1β does not induce utrophin or genes of the NMJ.
Finally, we use an inducible transgenic model to show
that induction of PGC-1α well after birth can still confer
efficient protection against dystrophy, a more plausible
therapeutic scenario.
Methods
Animals
All animal experiments were performed according to pro-
cedures approved by the Beth Israel Deaconess Medical
Center’s Institutional Animal Care and Use Committee.
C57BL/10ScSn-Dmd
mdx/J mice (mdx mice) [37] and
Utrn
tm1JrsDmd
mdx/J mice (mdx/utrn
-/- mice) [11,13] were
obtained from Jackson Laboratories (Bar Harbor, Maine,
USA). These mice were crossed with: muscle-specific
PGC-1α transgenic mice (MCK-PGC-1α)[ 3 8 ] ;m u s c l e -
specific PGC-1β transgenic mice (MCK-PGC-1β) [39];
or mice with inducible PGC-1α that possess the muscle
specific tetracycline-dependent activator (MCK-tTA)
and the PGC-1α coding region under control of the tet-
response element promoter (TRE-PGC-1α)t r a n s g e n i c
genes (Ind_PGC-1α) [40]. mdx, mdx/MCK-PGC-1α,
mdx/MCK-PGC-1β and mdx/Ind_PGC-1α are products
of crosses between animals in the C57/BL/6J background
(MCK-PGC-1α, MCK-PGC-1β and Ind_PGC-1α mice)
and C57/BL/10ScSn (mdx mice) background. All non-
dystrophic mice, including wild-type (WT) controls were
in the C57/BL/6J background. The mdx/utrn
-/- mice
as provided by Jackson Laboratories are in a mixed
background. Therefore, all experimental groups with
these mice were conducted on sibling-mates in mixed
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PGC-1β and mdx/utrn
-/-/MCK-PGC-1α mice were ana-
lyzed at 5 weeks of age, while exercise experiments were
performed on 10-week-old mice (n = 5 per experimental
group). mdx/Ind_PGC-1α were induced by removal of
doxycycline from chow at 3 weeks of age and experiments
performed at 7 weeks of age (n = 5 per experimental
group).
Growth curves and radiograph
Body weight and body length (nose to tail base) of litter
mates from mdx/utrn
+/- /MCK-PGC-1α male crossed
with mdx/utrn
+/- females was measured in a blinded
fashion from 5 weeks to 15 weeks of age. Radiographs
of representative animals in each genotype were taken
of anesthetized animals at 13 weeks of age.
Treadmill exercise
Ten-week-old mice were run for 1 hour or until exhaustion
o nat r e a d m i l la ta1 5 °d o w n h i l la n g l e( 1
st run). Treadmill
speed was steadily increased, starting at 10 m/minute for 5
minutes, then increasing to 15 m/minute for 5 minutes,
20 m/minute for 5 minutes, and finally 25 m/minute for
45 minutes. Blood was drawn 2 hours after the run. This
exercise protocol was repeated after a 24 hour resting
period (2
nd run). Mice were sacrificed 2 hours after the
2
nd run.
Cell culture
Primary satellite cells were isolated and cultured from
the entire hind limb of WT mice as previously described
[41,42]. Cells were differentiated into myotubes using
DMEM with 5% horse serum for 72 hours. Cells were
then infected with control (GFP) adenovirus (WT), re-
combinant PGC-1α adenovirus (Ad-PGC-1α) or recom-
binant PGC-1β adenovirus (Ad-PGC-1β) at multiplicity
of infection of 10 to 30 [43]. Cells were analyzed 48
hours later.
Evans blue injection and histological analysis
For Evans Blue assay, mice were injected with 1% solu-
tion intraperitoneally at a final concentration of 1% vol-
ume to body weight 16 hours prior to sacrifice. Tissues
were dissected and embedded in OCT compound (VWR,
Radnor, Pennsylvania, USA) and flash-frozen. Evans Blue
was analyzed by fluorescence microscopy. Sections were
also stained with rabbit polyclonal anti-laminin antibody
(Abcam, ab11575, Cambridge, Massachusetts, USA) in
order to establish fiber boundaries. We used two different
staining techniques in this report to calculate centralized
nuclei: i) frozen sections were stained with anti-laminin
and counterstained with 4',6-diamidino-2-phenylindole
(DAPI); ii) tissue was dehydrated and embedded in paraf-
fin and sectioned before hematoxylin and eosin staining.
In either case, 20 images were taken at 200× and the
number of centralized nuclei to overall number of nuclei
counted in a blinded fashion.
Serum creatine kinase assay
Blood was collected and serum isolated using heparin-
coated collection tubes, either by heart puncture or cheek
bleed [44,45] Serum Creatine kinase activity was then
determined with a Genzyme Creatine Kinase-SL Assay
Kit (BioPacific Diagnostic Inc, Vancouver, BC, Canada).
Real-time polymerase chain reaction
Total RNA was isolated from mouse tissue using the
TRIzol (Invitrogen, Grand Island, NY, USA) reagent,
while RNA from cultured cells was isolated using the
Turbocapture (Qiagen, Valencia, California, USA) method.
Samples for real-time PCR analyses were reverse tran-
scribed (Applied Biosystems, Foster City, California, USA),
and quantitative real-time PCRs (qPCRs) were performed
on the cDNAs in the presence of fluorescent dye (SYBR
green) (Bio-Rad, Hercules, California, USA). Relative ex-
pression levels were determined using the comparative
cycle threshold method [46].
Western blotting
Protein from quadriceps (100 μg) was run on a 4% poly-
acrylamide gel, transferred to nitrocellulose membrane,
and blotted for utrophin using an anti-utrophin antibody
(H-300, Santa Cruz Biotech, Santa Cruz, California USA).
As a control, equivalent protein was run on a 10% poly-
acrylamide gel, transferred and probed with anti-pan-
actin antibody (Cell Signaling Technology Inc, Boston,
Massachusetts, USA),
Statistical analysis
The data are presented as means ± SEM. Statistical ana-
lysis was performed with Student’s t-test for all in vitro
experiments, analysis of variance for all in vivo experi-
ments, and Log-rank (Mantel-Cox) test for the Kaplan–
Meier curves. P values <0.05 were considered statistically
significant.
Results
PGC-1β, in contrast to PGC-1α, does not induce expression
of utrophin and other neuromuscular junction genes
We began our studies by investigating the role of PGC-
1β, if any, in the pathogenesis of, and possible protec-
tion against, muscle dystrophy. Increased PGC-1α has
been shown to ameliorate muscle damage in mdx mice
[17,31-34]. PGC-1α has also been shown to be de-
creased in a dog model of DMD [47], suggesting that
loss of PGC-1α protection may contribute to the dys-
trophy. Similarly, we found that PGC-1α mRNA ex-
pression, measured by qPCR, is significantly reduced
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(Figure 1A). In contrast, expression of PGC-1β was not
decreased in mdx mice, suggesting that PGC-1β may
play a different role than PGC-1α in mdx pathogenesis.
Because the anti-dystrophic effects of PGC-1α have
widely been ascribed to induction of the NMJ, and
utrophin in particular, we next tested if PGC-1β also
regulates this program. Five-week-old male mice with
transgenic overexpression of PGC-1α in muscle cells
(MCK-PGC-1α) showed significant increase in expression
of genes involved in the NMJ (for example, utrophin,
acetylcholine receptor (AChR)α, AChRδ,A C h R ε, acetyl-
choline esterase (AChEst), ErbB-2, GABPA, MUSK and
Rapsyn) in the gastrocnemius, compared to littermate
control animals (WT) (Figure 1B). Unlike PGC-1α,h o w -
ever, equivalent transgenic increase in PGC-1β expression
in muscle cells (MCK-PGC-1β) did not increase expres-
sion of genes of the NMJ (Figure 1B). In contrast, genes
associated with oxidative phosphorylation (ox-phos) were
significantly induced by transgenic overexpression of
both PGC-1α and PGC-1β, as published previously
[24]. Induction of ox-phos genes was equivalent if not
slightly higher in MCK-PGC-1β animals, demonstrating
that the non-induction of genes of the NMJ cannot be
explained by poor activity of the transgenic PGC-1β.
Unbiased microarray analyses of RNAs from the quadri-
ceps of MCK-PGC-1β mice versus littermate controls
similarly revealed increased expression of mitochondrial
genes compared to WT, but no change in genes of the
NMJ (Figure 1C). Similarly, in cultured differentiated
primary myotubes, infection with recombinant PGC-1α
adenovirus (Ad-PGC-1α) increased expression of both
NMJ genes and ox-phos genes, while infection with re-
combinant PGC-1β (Ad-PGC-1β) induced only ox-phos
genes and had no effect on NMJ genes (Figure 1D). To-
gether, these results indicate that, unlike PGC-1α,P G C - 1 β
does not regulate expression of NMJ genes or utrophin in
muscle cells or in vivo.
PGC-1β prevents damage in dystrophic muscle
The prevailing model of the mechanism by which PGC-
1α ameliorates muscle damage is by positively regulating
expression of genes of the NMJ, including utrophin. The
above results demonstrating that PGC-1β does not induce
this program thus suggest that PGC-1β transgenesis
would fail to recapitulate the protection against dystrophy
seen in PGC-1α transgenic animals. To test this notion,
we crossed mdx animals with MCK-PGC-1β (and, as
Figure 1 Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1β, in contrast to PGC-1α, does not induce expression of
utrophin and other neuromuscular junction (NMJ) genes. (A) Expression of PGC-1α and PGC-1β in the gastrocnemius of 5-week-old male
control (wild-type; WT) and dystrophin-deficient (mdx) mice was examined by isolating mRNA, performing reverse transcription, followed by
quantitative PCR (n = 4). (B) Five-week-old male mice with transgenic overexpression of PGC-1α in muscle cells (MCK-PGC-1α), or male mice with
transgenic overexpression of PGC-1β in muscle cells (MCK-PGC-1β) (n = 5 each group). Genes of the NMJ and genes involved in oxidative
phosphorylation (Ox-Phos) were analyzed. Bars depict relative mRNA expression. (C) Heat map of the 25 most highly expressed mitochondrial
genes (left) and the 25 most highly expressed NMJ genes (right) from microarrays of RNA isolated from quadriceps of WT and MCK-PGC-1β mice.
(D) Primary myotubes in cell culture were infected with control adenovirus (WT), recombinant PGC-1α adenovirus (Ad-PGC-1α) or recombinant
PGC-1β adenovirus (Ad-PGC-1β). Cells were harvested 48 hours after infection and mRNA expression determined by quantitative PCR. Bars depict
relative mRNA expression, error bars represent SEM. *P < 0.05. AChR, acetylcholine receptor.
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pression of PGC-1α in mdx mice (mdx/MCK-PGC-1α)i n -
creased mRNA expression of NMJ genes and utrophin, as
published previously (Figure 2A). Transgenic expression
of PGC-1β (mdx/MCK-PGC1β) did not induce this pro-
gram, echoing the findings in non-dystrophic mice (Fig-
ure 1). Both PGC-1α and PGC-1β induced the expression
of ox-phos genes (Figure 2A). Utrophin protein was in-
duced in mdx/MCK-PGC-1α quadriceps compared to
quadriceps from mdx mice alone (Figure 2B), while mdx/
MCK-PGC-1β mice showed no significant increase in
utrophin protein. Therefore, unlike PGC-1α,P G C - 1 β does
not induce utrophin or other proteins of the NMJ in mdx
mice.
Next, we performed various experiments to determine
t h er e l a t i v ea m o u n to fd a m a g ea n df u n c t i o ni nm d x ,
mdx/MCK-PGC-1α,a n dm d x / M C K - P G C - 1 β mice. We
first tested the level of serum creatine kinase. There was
significant increase in free creatine kinase in the serum
of mdx compared to WT mice (Figure 2C), consistent
with increased muscle damage. The amount of serum
creatine kinase was significantly suppressed in mdx/
MCK-PGC-1α compared to mdx alone, as previously
shown [17], consistent with amelioration of dystrophy by
PGC-1α expression. Surprisingly, mdx/MCK-PGC-1β also
had significantly lower levels of serum creatine kinase
compared to mdx alone, suggesting that PGC-1β is also
protective in the mdx model.
We next stained cross-sections of the gastrocnemius
with hematoxylin and eosin (Figure 2D). We observed that
mdx mice had a greater number of centralized nuclei and
smaller fiber size as previously reported [48]. Increased
transgenic expression of PGC-1α appeared to improve
these phenotypes (Figure 2D). In order to better visualize
and quantify these differences, we stained cross-sections
of the gastrocnemius with anti-laminin to stain boundary
of muscle fibers and counterstained with DAPI. Consistent
with previous studies, mdx mice had a larger variation in
fiber size and a larger proportion of small fibers compared
to WT mice [48] (Figure 2E). The muscle fibers in mdx/
MCK-PGC-1α had a lower variation in size, and had fewer
small fibers compared to mdx alone. Muscle fibers in the
mdx/MCK-PGC-1β were similar to mdx/MCK-PGC-1α.
PGC-1β transgenesis thus partly rescued the fiber size de-
fect seen in mdx mice. We next measured the percentage
of nuclei found in the center of muscle fibers (Figure 2F),
an established model of estimating the number of post-
damage regenerating fibers. The number of centralized
nuclei in gastrocnemius of the mdx mice was approxi-
mately 17%, while essentially no central nuclei were seen
in WT animals. mdx/MCK-PGC-1α mice had approxi-
mately 50% decrease in the number of centralized nuclei,
consistent with partial rescue of the mdx phenotype. The
number of centralized nuclei in mdx/MCK-PGC-1β mice
was similarly reduced compared to mdx alone. Similar
findings were seen in quadriceps and tibialis anterior (data
not shown).
The extravasation of Evans Blue dye into the muscle of
mice is a standard measure of vascular and sarcolemmal
integrity. As shown in Figure 2G, there was a significant
increase in the amount of Evans Blue leakage into the
gastrocnemius, the quadriceps and the tibialis anterior
of mdx mice compared to WT, consistent with muscle
damage and necrosis in mdx mice. Increased expression
of PGC-1α in mdx/MCK-PGC-1α mice lowered the in-
tensity of Evans Blue dye in the different muscles, as
previously reported [17]. Surprisingly again, increased
expression of PGC-1β in mdx/MCK-PGC-1β reduced
Evans Blue extravasation equally effectively (Figure 2G).
PGC-1β improves exercise capacity of dystrophic mice
We next tested the effect of PGC-1α or PGC-1β on mdx
mice subjected to eccentric physical exercise:- that is,
downhill running. The muscle damage observed in mdx
mice subjected to eccentric exercise more closely resem-
bles muscle damage seen in DMD patients [49]. WT,
mdx, mdx/MCK-PGC-1α and mdx/MCK-PGC-1β mice
were made to run on a treadmill for 1 hour at an decline
of 15° downhill. This exercise regimen was repeated 24
hours after the first run. WT mice were able to complete
this exercise regimen, but mdx mice were exhausted
within the first 5 to 10 minutes of the regimen (Figure 3A),
as shown previously [17]. Both mdx/MCK-PGC-1α and
mdx/MCK-PGC-1β mice were able to run for significantly
longer compared to mdx alone on both the 1
st and 2
nd
run (Figure 3A). Serum was drawn from the animals 2
hours after each run, and serum creatine kinase measured.
There was significant increase in creatine kinase of
mdx mice compared to WT mice, consistent with signifi-
cant induction of muscle damage by eccentric exercise
(Figure 3B). Compared to mdx alone, both mdx/MCK-
PGC-1α and mdx/MCK-PGC-1β had significantly lower
levels of serum creatine kinase, consistent with lower
levels of muscle damage (Figure 3B). In fact, the improve-
ment in creatine kinase leak seen in MCK-PGC-1 mice is
likely an underestimate of true improvements conferred
by PGC-1 transgenesis, because the transgenic mice were
able to run longer than the mdx controls. Similarly,
muscle damage as determined by Evans Blue leakage into
t h em u s c l ef i b e r sw a sl o w e ri nt h em d x / M C K - P G C - 1 α and
mdx/MCK-PGC-1β compared to mdx alone (Figure 3C).
Together, these results indicate that overexpression of
PGC-1α or PGC-1β prevents muscle damage in mdx
mice in response to eccentric physical exercise.
Taken together, these data show that PGC-1β is as ef-
fective as PGC-1α in ameliorating muscle damage in
both sedentary and eccentrically exercised mdx mice. As
described above, however, overexpression of PGC-1β in
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components of the NMJ. This observation strongly sug-
gests that the mechanism by which PGC-1α and PGC-1β
ameliorates muscle damage in mdx mice is not related to
induction of components of the NMJ.
Increased PGC-1α expression in dystrophic muscle
ameliorates damage in the absence of utrophin
As outlined above, our results with MCK-PGC-1β mice
support the hypothesis that the beneficial impact of
PGC-1α in mdx mice occurs independently of utrophin
induction. We next directly tested this hypothesis by
using mice that lack both dystrophin and utrophin (mdx/
utrn
-/-). Previous reports have shown that these mice suf-
fer from a more severe dystrophy compared to mdx mice
alone [11-13]. The progression of dystrophy and reduced
lifespan of these mice more closely recapitulates pro-
gression of DMD in humans [15]. We first tested the ef-
fect of overexpression of PGC-1α in muscle of these
mice (mdx/utrn
-/-/MCK-PGC-1α) on induction of NMJ
and ox-phos genes. Similar to mdx mice, components of
NMJ and ox-phos genes were induced in the mdx/utrn
-/-
mice (Figure 4A). The mutation in the utrn gene results in
premature translation termination, and utrophin mRNA
is still present (as previously reported [11]) and induced
by PGC-1α (Figure 4A). However, utrophin protein is
Figure 3 Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α and PGC-1β improve muscle function in exercising
dystrophin-deficient (mdx) mice. (A) Ten-week-old control (wild-type; WT), mdx, mdx mice with transgenic overexpression of PGC-1α in muscle
cells (mdx/MCK-PGC-1α), or mdx mice with transgenic over-expression of PGC-1β in muscle cells (mdx/MCK-PGC-1β) (n = 5 each group) were run
for 1 hour or until exhaustion on a treadmill at a 15° downhill angle with steadily increasing speed as described in the methods (1
st run). This
exercise protocol was repeated after a 24 hour resting period (2
nd run). Bars depict average running time. (B) Two hours after the first run, blood
was drawn from mice by submandibular bleeding. Serum creatine kinase was determined (1
st run). Two hours after the second run, mice were
sacked and blood was drawn. Serum creatine kinase was determined (2
nd run). (C) Evans Blue was injected intraperitoneally 16 hours before
sacking and histological sections from gastrocnemius were analyzed by fluorescence microscopy. Error bars represent SEM. *P < 0.05.
(See figure on previous page.)
Figure 2 Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1β ameliorates muscle damage in dystrophin-deficient
(mdx) mice without induction of utrophin or other neuromuscular junction (NMJ) genes. (A) Five week old control (WT), mdx, mdx mice
with overexpression of PGC-1α in muscle cells (mdx/MCK-PGC-1α), or mdx mice with overexpression of PGC-1β in muscle cells (mdx/MCK-PGC-1β)
(n = 5 each group) were sacked, and quantitative PCR was performed on mRNA isolated from the gastrocnemius. Genes of the NMJ and genes
involved in oxidative phosphorylation (Ox-Phos) were analyzed. (B) Quadriceps from mdx, mdx/MCK-PGC-1α and mdx/MCK-PGC-1β were
harvested and subjected to immunoblot analysis with anti-utrophin antibody and anti-pan-actin antibody. Results are representative of three
independent experiments. (C) Five-week-old WT, mdx, MCK-PGC-1α and MCK-PGC-1β mice were sacked and serum creatine kinase activity was
measured. Bars depict average serum creatine kinase activity (n = 5). (D) Histological sections from gastrocnemius of 5-week-old WT, mdx,
MCK-PGC-1α and MCK-PGC-1β mice were prepared and stained with hematoxylin and eosin. Black arrows indicate centralized nuclei. (E) Histological
sections from gastrocnemius of 5-week-old WT, mdx, MCK-PGC-1α and MCK-PGC-1β mice were stained with anti-laminin (green) to show muscle fiber
boundaries and 4',6-diamidino-2-phenylindole (DAPI) to stain nuclei (blue). Representative images shown (left), with red arrows indicating centralized
nuclei. Bars (right) depict percentage of nuclei counted which were centralized (n = 5). (F) Images of the same section were analyzed for relative fiber
size using ImageJ. Bar histograms represent size distribution of the muscle fibers (right). (G) Five-week-old WT, mdx, MCK-PGC-1α and MCK-PGC-1β
mice were injected intraperitoneally with 1% v/w Evans Blue solution and sacrificed 16 hours later. Histological sections from gastrocnemius, quadriceps
and tibialis anterior were analyzed for dye incorporation into muscle fibers by fluorescence microscopy. Representative images are presented. Error bars
represent SEM. *P < 0.05. AChR, acetylcholine receptor.
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-/- and mdx/utrn
-/-/MCK-PGC-1α mice
(Figure 4B), as expected.
We next tested the effects of PGC-1α expression on
muscle damage in mdx/utrn
-/- mice. Serum creatine kin-
ase levels were higher in mdx/utrn
-/- mice compared to
mdx alone, consistent with a more severe progression of
dystrophy (Figure 4C). PGC-1α expression reduced serum
creatine kinase by 47%, comparing mdx/utrn
-/-/MCK-
PGC-1α mice to mdx/utrn
-/- alone. This is similar to the
46% reduction in serum creatine kinase with expression of
PGC-1α in mdx mice (Figure 4C), demonstrating that
PGC-1α protects against muscle dystrophy as efficiently in
the absence of utrophin as in its presence. Similar results
were observed with Evans Blue incorporation experiments.
Evans Blue staining in the fibers of the gastrocnemius and
diaphragm was higher in mdx/utrn
-/- mice compared to
mdx mice (Figure 4D), and the intensity of staining was
markedly reduced in mdx/utrn
-/-/MCK-PGC-1α com-
pared to mdx/utrn
-/- alone (Figure 4D).
The mdx/utrn
-/- mice suffer from poor growth, signifi-
cant kyphosis and reduced life-span compared to mdx
mice [12,13]. We examined if overexpression of PGC-1α
in skeletal muscle would affect any of these phenotypes.
Physical examination of 5-week-old mice revealed that
the mdx/utrn
-/- mice were smaller and appeared more
hunched compared to mdx mice. In comparison, mdx/
utrn
-/-/MCK-PGC-1α mice appeared larger than mdx/
utrn
-/- mice (Figure 5A) and appeared indistinguishable
from mdx mice. Radiography of mdx/utrn
-/- revealed
severe kyphosis compared to mdx mice (Figure 5B). In
contrast, kyphosis in mdx/utrn
-/-/MCK-PGC-1α was
largely absent (Figure 5B). Body weight and body length
(nose to tail) of mdx, mdx/MCK-PGC-1α,m d x / u t r n
-/-,
and mdx/utrn
-/-/MCK-PGC-1α mice were measured be-
tween 5 and 15 weeks of age (Figure 5C). There was no
significant difference in body weight or length between
mdx and mdx/MCK-PGC-1α mice. mdx/utrn
-/-,h o w -
ever, were significantly lighter and smaller compared to
mdx mice alone (Figure 5C). In contrast, mdx/utrn
-/-/
MCK-PGC-1α mice were heavier, and had longer body
length compared to mdx/utrn
-/- mice. The life span of
mdx mice is reported to be up to 2 years. The life span
Figure 4 Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α ameliorates muscle damage in dystrophin/utrophin-
deficient mice. (A) Five-week-old dystrophin-deficient male mice (mdx), PGC-1α muscle-specific transgenic in an mdx background (mdx/MCK-PGC-1α),
dystrophin/utrophin-deficient mice (mdx/utrn
-/-), and PGC-1α muscle-specific transgenic in dystrophin/utrophin-deficient mice (mdx/utrn
-/-/MCK-PGC-1α)
were sacrificed and quantitative PCR performed on gastrocnemius (n = 5 per group). Bars depict relative mRNA expression, error bars represent SEM.
(B) Quadriceps from 5-week-old mdx, mdx/utrn
-/- and mdx/utrn
-/-/MCK-PGC-1α were harvested and subjected to immunoblot analysis with anti-
utrophin antibody and anti-pan-actin antibody as loading control. Results are representative of three independent experiments. (C) Five-week-old male
mdx, mdx/MCK-PGC-1α,m d x / u t r n
-/- and mdx/utrn
-/-/MCK-PGC-1α mice were sacked and blood was drawn. Serum creatine kinase was measured. Bars
represent average level of serum creatine kinase. Error bars represent SEM (n = 5). (D) Evans Blue was injected intraperitoneally 16 hours before sacking
into 5-week-old male mdx, mdx/MCK-PGC-1α,m d x / u t r n
-/- and mdx/utrn
-/-/MCK-PGC-1α. Histological sections from gastrocnemius and diaphragm were
analyzed by fluorescence microscopy. *P < 0.05. AChR, acetylcholine receptor.
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-/- mice, in contrast, is shortened, with
all mice in our cohort dying at between 13 and 17 weeks
of age (Figure 5D). The mdx/utrn
-/-/MCK-PGC-1α mice
showed an increase in life span, with 60% of mice
remaining alive after 18 weeks (compared to 0% of
mdx/utrn
-/- mice) (P <0 . 0 2v e r s u sm d x / u t r n
-/- mice).
Together, these results demonstrate that overexpres-
sion of PGC-1α in muscle rescues dystrophy independ-
ently of utrophin. The results also show that muscle
PGC-1α dramatically improves myopathy and whole-
body sequelae in mdx/utrn
-/- mice, a more severe dys-
trophic model that more closely approximates the hu-
man disease.
Postnatal increase in PGC-1α expression in muscle
improves dystrophic muscle
The above experiments underscore PGC-1α as a potential
therapeutic target for DMD. However, in all of these mice
as well as those previously published [17], PGC-1α overex-
pression in skeletal muscle begins in utero.D y s t r o p h i n -
deficient muscle reveals significant abnormalities even
prenatally [35,36], suggesting that prenatal expression of
PGC-1α may have had important beneficial effects that
would be difficult to recapitulate in the clinical setting.
We thus wanted to test if post-natal increase in PGC-1α
expression can reduce muscle damage in mdx mice. To
conduct this experiment, we used double-transgenic mice
(MCK-tTA/TRE-PGC-1α) as described in Figure 6A and
the Methods section. Induction of PGC-1α thus occurs
only with removal of doxycycline from chow (Figure 6A).
These mice were then additionally bred into the mdx
background. Mice were switched to chow lacking doxy-
cycline at the age of 3 weeks and were examined 4
weeks later. We first confirmed that induction of PGC-
1α was successful, observing an approximate 4-fold in-
crease in PGC-1α expression, both in mdx and WT
backgrounds (Figure 6B), and mildly less than observed
in constitutive mdx/MCK-PGC-1α mice (Figure 2A).
We also observed corresponding increase in NMJ and
ox-phos genes with PGC-1α induction in both genetic
backgrounds (Figure 6B).
We next tested if induction of post-natal induction of
PGC-1α affects dystrophic muscle damage in mdx mice.
Serum creatine kinase was significantly reduced by 28%
(Figure 6C) after PGC-1α induction. Evans Blue staining
of muscle was also reduced in mdx/Ind_PGC-1α mice
compared to mdx mice (Figure 6D). Lastly, we exam-
ined the number of central nuclei found within the
muscle fibers, an established measure of post-damage
regenerating fibers in mice. There were no centralized
Figure 5 Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α reverses poor growth and kyphosis in dystrophin/
utrophin-deficient mice. (A) Photograph of representative 5-week-old dystrophin deficient male mice (mdx), PGC-1α muscle-specific trans-
genic in an mdx background (mdx/MCK-PGC-1α), dystrophin/utrophin-deficient mice (mdx/utrn
-/-), and PGC-1α muscle-specific transgenic in
dystrophin/utrophin-deficient mice (mdx/utrn
-/-/MCK-PGC-1α) indicating difference in size and pronounced kyphosis in mdx/utrn
-/- that is
largely reversed in mdx/utrn
-/-/MCK-PGC-1α animals. (B) Representative radiograph of 13-week-old male mdx, mdx/MCK-PGC-1α, mdx/utrn
-/-
and mdx/utrn
-/-/MCK-PGC-1α mice showing small size and pronounced kyphosis in mdx/utrn
-/- mice is largely reversed in mdx/utrn
-/-/MCK-
PGC-1α mice. (C) Body weight (left) and body length from nose to tail base (right) of mdx (n = 8), mdx/MCK-PGC-1α (n = 8), mdx/utrn
-/- (n
= 5) and mdx/utrn
-/-/MCK-PGC-1α (n = 5) male mice were measured every 2 weeks from 5 to 15 weeks of age. Graph represents average
body weight and average body length, error bars SEM. (D) Kaplan-Meier survival plot of mdx (n = 8), mdx/MCK-PGC-1α (n = 8), mdx/utrn
-/-
(n = 5) and mdx/utrn
-/-/MCK-PGC-1α (n = 5) male mice with time. P < 0.02 by Log-rank (Mantel-Cox) test for mdx/utrn
-/- compared to
mdx/utrn
-/-/MCK-PGC-1α cohorts.
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approximately 18% of nuclei in mdx mice were found in
the center of cells (Figure 6E). Induction of PGC-1α
significantly decreased the number of centralized nuclei
by 58% compared to mdx mice. From these results, we
conclude that post-natal induction of PGC-1α is able to
efficiently prevent muscle damage in mdx mice.
Discussion
We demonstrate in this study that: both PGC-1α and
PGC-1β improve muscle function in dystrophic mouse
models; that they do so independently of utrophin induc-
tion; that PGC-1α improves muscle function even if deliv-
ered only post-natally; and that even the more severe mdx/
utrn
-/- model of DMD is efficiently rescued by PGC-1α.
The induction of utrophin efficiently rescues the ab-
sence of dystrophin in muscle [2,3,10,16,50] and has
thus generally been assumed to explain the benefits
conferred by PGC-1α [17,31,33]. The present study,
however, demonstrates that this is not the case. The
data demonstrate the existence of other beneficial path-
ways. Identifying these pathways will be of great interest,
especially in light of the efficient protection afforded by
PGC-1α induction. A number of potential mechanisms
exist. ATP deficiency may contribute to myocyte death,
and PGC-1 induction, leading to mitochondrial biogen-
esis and increased OXPHOS capacity, significantly in-
creases the capacity for ATP generation. Mitochondria
also provide a large buffer for cytosolic calcium, and cyto-
solic calcium overload in dystrophic muscle is thought to
contribute to the activation of calpains and caspases, ul-
timately leading to myocyte apoptosis. PGC-1-induced
mitochondrial biogenesis may thus buffer cytosolic cal-
cium and help prevent these events. PGC-1s have also
Figure 6 Post-natal expression of peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α ameliorates muscle damage
in dystrophin-deficient (mdx) mice. (A) The inducible PGC-1α mouse (Ind_PGC-1α) possess two transgenic genes: the muscle specific
tetracycline-dependent activator (MCK-tTA); and PGC-1α coding region under control of the tet-response element promoter (TRE_PGC-1α).
Removal of doxycycline (dox) allows tTA to bind the TRE region and increase expression of PGC-1α. Mice were kept off dox for 4 weeks (from 3
to 7 weeks of age) prior to the experiment. (B) Nine-week-old male control (wild-type; WT), inducible PGC-1α muscle-specific transgenic mice
(WT/Ind_PGC-1α), mdx, and inducible PGC-1α muscle-specific transgenic mice in an mdx background (mdx/Ind_PGC-1α) were sacked and
quantitative PCR performed on mRNA from gastrocnemius (n = 5 per group). Bars depict relative mRNA expression. (C) Seven-week-old WT, WT/
Ind_PGC-1α, mdx and mdx/Ind_PGC-1α mice were sacked and blood was drawn. Serum creatine kinase was measured. Bars represent average
level of serum creatine kinase. (D) Evans Blue was injected intraperitoneally 16 hours before sacking into 7-week-old old WT, WT/Ind_PGC-1α,
mdx and mdx/Ind_PGC-1α mice. Histological sections from gastrocnemius were analyzed by fluorescence microscopy. (E) Histological sections
from quadriceps of 7-week-old WT, WT/Ind_PGC-1α, mdx and mdx/Ind_PGC-1α mice were stained with hematoxylin and eosin. The number of
nuclei found in the center of the cell as opposed to on the periphery was counted. Representative images shown (left) with small black arrows
indicating centralized nuclei. Bars (right) depict percentage of nuclei counted which were centralized (n = 5). Error bars represent SEM. *P < 0.05.
AChR, acetylcholine receptor; NMJ, neuromuscular junction; Ox-phos, oxidative phosphorylation.
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to reduce cellular levels of reactive oxygen species (ROS)
[51-53], and ROS have also been implicated in dystrophic
pathophysiology [54-57]. Finally, PGC-1α may suppress
the susceptibility of mitochondrial permeability transition
pore (PTP) to open [58], again minimizing the tendency
to apoptosis. The fact that one or more of these mecha-
nisms must underlie the powerful PGC-1α-mediated pro-
tection underscores the need to better understand these
processes.
Despite the fact that it does not induce genes of the
NMJ, our data supports the use of PGC-1β as a possible
alternative therapeutic target in DMD. Why PGC-1β fails
to induce utrophin and other NMJ genes is not clear.
PGC-1β likely interacts efficiently with NRF2, because it
strongly induces mitochondrial genes [19,24]. The specific
inability to induce genes of the NMJ thus likely does
not stem from an inability to bind GABPA/B tetramers
(NRF2). Post-translational modification of GABPA and
PGC-1α by p38MAPK has been shown to be important
for induction of NMJ genes [17], and this process may
differ with PGC-1β. The p38MAPK sites in PGC-1α
are, for example, not conserved in PGC-1β.
PGC-1α and β strongly drive the formation of oxida-
tive fibers at the expense of glycolytic fibers [38-40].
DMD in humans has been shown to affect type II glyco-
lytic fibers more severely than type I oxidative fibers
[59]. This observation has been attributed to the obser-
vation that utrophin expression is higher in oxidative
fibers, and that utrophin protein in these fibers can be
found extra-synaptically, where it would more easily
compensate for loss of dystrophin [32,60]. Our current
work would suggest, however, that utrophin expression
and distribution does not underlie these differences in
myofiber susceptibility to DMD, underscoring the need
to better understand other protective mechanisms in-
duced by the PGC-1s.
Dystrophy in mdx/utrn
-/- mice is much more severe
than in mdx mice alone. The mice undergo significant
muscle degeneration early in life, with pronounced sys-
temic consequences such as kyphosis, delayed growth,
and eventual premature death by 3 to 4 months of age
[11-14]. mdx mice, on the other hand, recover effi-
ciently from their repeated bouts of dystrophy, do not
have overt systemic phenotypes, and have a normal life
span [15,61]. The mdx/utrn
-/- mouse model thus reca-
pitulates the clinical spectrum of human DMD much
more faithfully than do mdx mice. Our data showing
that PGC-1α transgenesis efficiently rescues all of these
phenotypes in mdx/utrn
-/- mice thus underscores the
potential clinical value of targeting PGC-1α and/or its
mechanism(s) of action. It will also be of interest to test
if PGC-1α can rescue other more severe models of
dystrophy, such as telomerase-deficient mice [62].
Together, these results strongly support PGC-1α as a
potential therapeutic target for DMD. One approach to
this target is gene therapy. Recent reports have suggested
that viral or plasmid delivery of PGC-1α post-natally
can improve muscle function in mdx mice [32,63]. Our
data support this conclusion, and show that PGC-1α ex-
pression specifically in myotubes likely mediates this
protection. Another approach could use pharmaceutical
activation of the PGC-1α pathway. Recent reports have
reported benefits in mdx mice with administration of
activators of AMPK, SIRT1, or PPARδ, all of which also
activate PGC-1α [34,64-66].
Conclusions
Our data demonstrate that increased expression of either
PGC-1α or PGC-1β in skeletal muscle ameliorates muscle
damage in mouse models of DMD. We show that this
benefit occurs independently of utrophin or increases in
NMJ components. We also demonstrate that post-natal
induction of PGC-1α is also beneficial in mdx mice, and
t h a te v e nt h em o r es e v e r em d x / u t r n
-/- model of DMD is
efficiently rescued by PGC-1α.P G C - 1 α and PGC-1β
thus represent viable therapeutic targets for DMD, but
the mechanisms by which they reduce muscle damage
in mouse models of DMD remain unclear and should
be the subject of future investigations.
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